A new type of anticancer drug, BP-1-102, has been created by a University of Hawaii Cancer Center team. The oral drug targets a key protein that causes the development of many types of cancer, including breast, lung, and skin cancers.
The development of BP-1-102 was conducted by a computer-based molecular analysis of the cancer-causing Stat 3 protein.
“The molecular structure of the hyperactive Stat3 protein basically resembles two cars that are joined together side-by-side,” said James Turkson, PhD, team leader. “We then utilized a computer program that creates molecular models of potential drugs engaging in binding to the Stat3 protein to craft the BP-1-102 drug which literally pulls apart the Stat3 protein rendering it ineffective in causing cancer.”
A unique feature of BP-1-102 is its high efficacy against cancer even when administered in oral form. Currently, most anticancer drugs require intravenous administration in a clinic or hospital setting. This factor can increase the emotional, financial, and physical burdens on cancer patients. Furthermore, BP-1-102, in experimental form, has shown potential in treating breast and lung cancers.
Source: UH Cancer Center.